5Murakami H, Newdrugs of the world: 2003[J]. Fain Kemikaru, 2004, 33(10): 49-56.
6Hecker S J, Erion M D. Prodrugs of phosphates and phosphonates[J]. J Med Chem, 2008, 51(8): 2328-2345.
7Sobue S, Tan K, Layton G, et al. The effects of renal impairment on the pharmacokinetics and safety of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole[J]. Br J Clin Phannacol, 57(6): 773-784.
8Sobue S, Tan K, et al. The effects of hepatic impairment on the pharmacokinetics of fosfluconazole and fluconazole following a single intravenous bolus injection offosfluconazole[J]. BrJClinPharmacol, 59(2): 160-166.
9Douglas S Johnson, Jie Jack Li. The Art of Drug Synthesis[M]. New York: John Wiley & Sons lnc, 2007: 71-82.
10Bentley A, Butters Michael, Green Stuart P, et al. The Discovery and Process Development of a Commercial Route to the Water Soluble Prodrug, Fosfluconazole[J]. Organic Process Research & Development, 6(2): 109-112.
